With over six years of experience in biotechnology and medical engineering, Max is the Chief Operating Officer at GelMEDIX, an early-stage ocular cell therapy company that is engineering the next generation of therapies to restore vision. He leads the business development, operations, and strategy for the company, leveraging his expertise in drug delivery, cell biology, and scientific management.Max is also a lecturer and a PhD graduate from MIT, where he conducted research on drug delivery and precision medicine assay development. He is passionate about translating scientific discoveries into innovative solutions that can improve the lives of patients and advance the field of regenerative medicine.
Listed skills include Research, Biotechnology, Matlab, Molecular Biology, and 17 others.